The myriad litigation and genetic diagnostic testing in Australia

This article details a study conducted to ascertain whether the Myriad litigation has had a discernible effect on the availability and pricing of genetic diagnostic testing in Australia. It concludes that the impacts of the litigation have been minimal. The great area of uncertainty for Australian testing resides with method patents, where scope for restrictive case law remains.